Dipal Doshi, CEO at Entrada Therapeutics, Inc. (TRDA), sold 1,000 shares at $15.00 ($15K) on 2024-02-15, disclosed to the SEC on 2024-02-20.
Scheduled sale ($15k) by CEO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| TRDA | SELL | 2024-05-20 | $45K | — | Filing → |
| TRDA | SELL | 2024-01-18 | $16K | — | Filing → |
| TRDA | SELL | 2023-12-22 | $15K | — | Filing → |